MLICM
NAVB

Metropolitan Life Insurance Company (MetLife)’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,703
Closed -$152K – 2547
2015
Q4 		$152K Buy
5,703
+19
+0.3% +$660 ﹤0.01% 2428
2015
Q3 		$259K Buy
5,684
+811
+17% +$30.6K ﹤0.01% 2102
2015
Q2 		$157K Sell
4,873
-1,701
-26% -$49.4K ﹤0.01% 2528
2015
Q1 		$209K Sell
6,574
-29
-0.4% -$981 ﹤0.01% 2036
2014
Q4 		$250K Hold
6,603
– – ﹤0.01% 2247
2014
Q3 		$174K Buy
6,603
+6,516
+7,490% +$172K ﹤0.01% 2480
2014
Q2 		$3K Sell
87
-5,013
-98% -$162K ﹤0.01% 2765
2014
Q1 		$189K Hold
5,100
– – ﹤0.01% 2500
2013
Q4 		$211K Hold
5,100
– – ﹤0.01% 2433
2013
Q3 		$270K Buy
5,100
+2,609
+105% +$152K ﹤0.01% 2189
2013
Q2 		$133K Buy
+2,491
New +$124K ﹤0.01% 2619

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NAVB Position: Q1 2016 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2016, closing a stake of 5,703 shares — an estimated $152K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NAVB in Q2 2013 and held it in 11 quarters. The position peaked at $270K in Q3 2013. 74 funds tracked by Wall St. Rank hold NAVB as of Q1 2016.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2016 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,703 Navidea Biopharmaceuticals Inc. shares in Q1 2016, an estimated $152K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 11 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Navidea Biopharmaceuticals Inc. position peaked at $270K in Q3 2013.
  • 74 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2016.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2016, filed 16 May 2016.